David Wax Museum performs at Long's Park Summer Music Series [photos]
Aug 22, 2023From gamblers to Garland to game show host, local theater stages offer variety in August
Aug 18, 2023World Series champion Don Wert, a former Tigers third baseman, is 85 [video]
Aug 08, 2023Pirates and Phillies meet in series rubber match
Aug 10, 2023Phillies play the Marlins with 2
Aug 06, 2023Sirnaomics to Present Latest Developments on Two Proprietary Delivery Platforms at Upcoming Industry Conferences
News provided by
12 Jul, 2023, 20:45 CST
Share this article
HONG KONG, Germantown, Md. and SUZHOU, China, July 12, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", stock code: 2257, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, hereby announces that Sirnaomics' Senior Director of Technology Innovation, Dr. Weterings will present the latest developments on its of GalAhead™, GalNAc-RNAi therapeutic platforms and related pipeline programs at international industry conferences taking place in July. Sirnaomics' Vice President of Chemistry, Manufacturing, and Controls processes, Dr. Welch will present the Polypeptide Nanoparticle platform's technology, at international industry conferences taking place in August.
9th Annual Drug Delivery Systems Presentation Details
2nd Annual Oligonucleotides CMC & Analytical Development Summit Presentation Details
About Sirnaomics
Sirnaomics is an RNA therapeutics biopharmaceutical company with product candidates in preclinical and clinical stages that focuses on the discovery and development of innovative drugs for indications with medical needs and large market opportunities. Sirnaomics is the first clinical-stage RNA therapeutics company to have a strong presence in both Asia and the United States. Based on its proprietary delivery technologies: Polypeptide Nanoparticle Formulation and the 2nd generation of GalNAc conjugation, the Group has established an enriched drug candidate pipeline. Sirnaomics is currently holding a leadership position on advancing RNAi therapeutics for oncology application with multiple successes of its clinical programs for STP705 and STP707. STP122G represents the first drug candidate of GalAhead™ technology entering clinical development. With the establishment of the Group's manufacturing facility, Sirnaomics currently is undergoing a transition from a biotech company to a biopharma corporation. Learn more at: www.sirnaomics.com.
SOURCE Sirnaomics
Sirnaomics